Keros Therapeutics Inc expected to post a loss of $1.12 a share - Earnings Preview

Keros Therapeutics

01/05/2023 15:49

* Keros Therapeutics Inc  KROS.OQ   KROS.O  is expected
to show a
rise in quarterly revenue when it reports  results on May 3
(estimated). 
    * The Lexington Massachusetts-based  company is expected to
report
revenue of $216.67 thousand, according to the mean estimate from
6 analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for Keros Therapeutics
Inc is
for a loss of $1.12 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 1.6%
in the last three months. ​
    * Wall Street's median 12-month price target for Keros
Therapeutics Inc is $100​, above​ its last closing price
of $44.36. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -1.08       -1.10      -1.09     Beat    0.7
 Sep. 30 2022  -1.23       -1.23      -0.92     Beat    25.3
 Jun. 30 2022  -1.05       -1.06      -1.13     Missed  -6.8​
 Mar. 31 2022  -0.86       -0.86      -1.01     Missed  -17.1
 ​​Dec.        -0.97       -0.92      -0.30     Beat    67.3
 31 2021                                                
 Sep. 30 2021  -0.72       -0.72      -0.87     Missed  -20.4​
 Jun. 30 2021  -0.69       -0.65      -0.67     Missed  -2.3
 Mar. 31 2021  -0.59       -0.58      -0.68     Missed  -17.2
 This summary was machine generated May 1 at 14:49 GMT.  All
figures in US dollars  unless otherwise stated